Pharyngitis News and Research

RSS
REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Cinryze data on hereditary angioedema presented at EAACI 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers begin approved drugs screening for clinical use against rare diseases

Ochsner, Take Care Health announce new relationship

Ochsner, Take Care Health announce new relationship

Scientists identify new treatment to combat PFAPA syndrome in children

Scientists identify new treatment to combat PFAPA syndrome in children

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

FDA approves change to prescribing information for Gilead Sciences' Letairis

FDA approves change to prescribing information for Gilead Sciences' Letairis

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

New guideline provides evidence-based recommendation for children undergoing tonsillectomy

New report indicates that struggling economy may have reduced use of preventive care

New report indicates that struggling economy may have reduced use of preventive care

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

FDA approves Gamunex-C for primary immunodeficiency treatment

FDA approves Gamunex-C for primary immunodeficiency treatment

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Data shows Take Care Clinics’ quality of care exceeds national benchmarks

Data shows Take Care Clinics’ quality of care exceeds national benchmarks